RNS Number : 5505X
ReGen Therapeutics PLC
26 June 2008
Embargoed for 10am 26 June 2008
ReGen Therapeutics Plc
Study showing that ReGen's ColostrininTM protects hippocampal cells against beta-amyloid
and oxidative stress is to be presented at the
FENS Forum 2008
ReGen Therapeutics Plc ('ReGen' or 'the Company') announces the publication of a new study
showing that ReGen's ColostrininTM protects
hippocampal cells against beta-amyloid and oxidative stress. The research, which has been
performed by ReGen's collaborators at the Open
University, Milton Keynes, United Kingdom is to be presented as a poster at the FENS Forum
2008*, Geneva on 16 July 2008.
It has previously been shown that Colostrinin* can prevent beta-amyloid induced impairment of
learning in newly hatched chicks [1] and can
protect standardised laboratory neurological cells against beta-amyloid induced toxicity and
oxidative stress induced damage [2]. However,
the research presented at the FENS Forum is the first study to show these effects on isolated
hippocampal cells.
Commenting on the study, Professor Mike Stewart the senior investigator and scientific
advisor to ReGen said
"These findings are very significant as the hippocampus is one of the key brain areas
known to be affected in neurodegenerative diseases
such as Alzheimer's disease. It is of particular importance to note that Colostrinin* can
directly protect these neurons that have such an
important role in cognition and memory".
Percy Lomax, Chairman and Chief Executive of ReGen said
"This research gives us further confidence in promoting Colostrinin*/CogniSure* as a
nutraceutical for healthy brain ageing. Longer term
it adds to our belief that our peptide programme may be able to produce a pharmaceutical
product with utility in Alzheimer's disease and
other similar neurological disease conditions".
A copy of the full abstract is available at:
http://fens2008.neurosciences.asso.fr/pages/posters_sessions.html
(Poster session 7 - Wednesday, July 16, 09:30-13:00, Section P217 - C: Alzheimer's 4).Froud K., Saffrey M. J., Stewart M. G., Banks D. & Wardhaugh T.
* The FENS Forum is the premier European Neuroscience meeting of 2008
1. Boldogh, I, Kruzel, M. L Journal of Alzheimer's Disease 13 (2008) 303-321
2. Banks D, Stewart M. G. Soc Neurosci Abstr proceedings (2006) 674.5.
For further information:
Percy Lomax
ReGen Therapeutics Plc
Tel No 020 7153 4920
Roland Cornish/Felicity Geidt
Beaumont Cornish
Tel No 020 7628 3396
David Scott/Nick Bealer
Alexander David
Tel No 020 7448 9800
Adrian Duffield/Jon Davies
College Hill Associates
Tel No 020 7457 2020
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCKGGZVKKKGRZM
|